MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 Pipeline Review, H2 2017 [Report Updated: 29082017] Prices from USD $3500
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 Pipeline Review, H2 2017
Summary
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 pipeline Target constitutes close to 7 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report MAP Kinase Interacting SerineThreonine Protein Kinase 1 Pipeline Review, H2 2017, outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 MAP kinaseinteracting serine/threonineprotein kinase 1 is an enzyme encoded by the MKNK1 gene. It plays a role in the response to environmental stress and cytokines and regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7methylguanosinecontaining mRNA cap. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Undisclosed which include indications Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Diffuse Large BCell Lymphoma, Fragile X Syndrome, Lymphoma, Solid Tumor and Unspecified.
Furthermore, this report also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1
The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 1 MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
